Key statistics
On Wednesday, Citius Pharmaceuticals Inc (CTXR:NAQ) closed at 0.8993, 42.75% above the 52 week low of 0.63 set on Dec 24, 2025.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 0.83 |
|---|---|
| High | 0.90 |
| Low | 0.7902 |
| Bid | 0.8811 |
| Offer | 0.93 |
| Previous close | 0.8115 |
| Average volume | 623.83k |
|---|---|
| Shares outstanding | 20.76m |
| Free float | 20.27m |
| P/E (TTM) | -- |
| Market cap | 16.85m USD |
| EPS (TTM) | -3.84 USD |
Data delayed at least 15 minutes, as of Feb 11 2026 21:00 GMT.
More ▼
Press releases
- Citius Oncology Expands International Distribution of LYMPHIR™ to European Union Through Exclusive Agreement with Uniphar
- Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
- Citius Oncology, Inc. Reports Fiscal Year 2025 Financial Results and Provides Business Update
- Citius Oncology Announces Closing of $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
- Citius Oncology Announces $18 Million Concurrent Registered Direct Offering and Private Placement Priced At-The-Market Under Nasdaq Rules
- Citius Oncology Expands LYMPHIR™ Distribution to Turkey and Middle East Countries Through Exclusive Agreement with Er-Kim
- Citius Oncology Announces U.S. Commercial Launch of LYMPHIR™, a Novel Cancer Immunotherapy for Cutaneous T-Cell Lymphoma (CTCL)
- Citius Oncology to Exhibit at the 67th American Society of Hematology (ASH) Annual Meeting
- Citius Oncology to Advance Commercial Launch of LYMPHIR™ with Verix AI Integration
More ▼
